Home › Companies › PMV PHARMACEUTICALS INC. › 2024-2025
At PMV PHARMACEUTICALS INC.'s shareholder meeting held June 5, 2025, in the 2024-2025 proxy season, 57 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 184 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — PMV PHARMACEUTICALS INC.'s filing reports the proposal as not approved, with 37% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: PMV PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 9, 2025.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and PMV PHARMACEUTICALS INC.’s Form 8-K, filed June 9, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 5, 2025: 4 items on PMV PHARMACEUTICALS INC.’s Form 8-K, filed June 9, 2025: 1 approved · 1 not approved · 2 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore PMV PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are PMV PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 9, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Arnold Levine, Ph.D. | 26,723,192 | -- | -- | 5,118,916 | 8,760,485 | 84% | Not verified | — |
| Elect Director: Charles M. Baum, M.D., Ph.D. | 13,258,337 | -- | -- | 18,583,771 | 8,760,485 | 42% | Not verified | — |
| 2. Non-Binding Advisory Vote to Approve the Compensation of the Company's Named Executive Officers On a non-binding advisory basis, the compensation paid to the Company's named executive officers as described in its definitive proxy statement on Schedule 14A | 11,646,401 | 20,170,398 | 25,309 | -- | 8,760,485 | 37% | Not approved | — |
| 3. Ratification of Independent Registered Public Accounting Firm | 39,963,653 | 638,940 | 0 | -- | -- | 98% | Approved | — |
Source: PMV PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 9, 2025 — read the filing on EDGAR.
Each item below shows how the 57 asset managers that disclosed a PMV PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
84% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors: Arnold Levine, Ph.D.
PMV PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Arnold Levine, Ph.D.”): 26,723,192 for, 5,118,916 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 84% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 21 asset managers below reported 5,845,541 for, 8,451 withheld, 16,475 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,132,041 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 1,255,473 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 1,147,095 | 0 | 0 | 0 | For |
| Fidelity | 359,213 | 0 | 0 | 0 | For |
| BlackRock | 343,025 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 329,949 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 128,300 | 0 | 0 | 0 | For |
| Goldman Sachs | 55,214 | 0 | 0 | 0 | For |
| T. Rowe Price | 33,600 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 18,007 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 16,475 | 0 | Abstain |
| MASTER INVESTMENT PORTFOLIO | 16,133 | 0 | 0 | 0 | For |
| Equitable | 8,718 | 0 | 0 | 0 | For |
| Northern Trust | 6,462 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 6,343 | Withhold |
| Blackstone Alternative Investment Funds | 5,800 | 0 | 0 | 0 | For |
| Nationwide | 5,228 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 2,108 | Withhold |
| John Hancock | 919 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 208 | 0 | 0 | 0 | For |
| Guggenheim | 156 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
42% Plurality election · of votes cast
Description as filed by funds: Election of Class II Directors: Charles M. Baum, M.D., Ph.D.
PMV PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Charles M. Baum, M.D., Ph.D.”): 13,258,337 for, 18,583,771 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 42% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 21 asset managers below reported 2,156,510 for, 3,337,405 withheld, 376,552 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,132,041 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 0 | 0 | 0 | 1,255,473 | Withhold |
| ACAP Strategic Fund | 0 | 0 | 0 | 1,147,095 | Withhold |
| Fidelity | 0 | 0 | 0 | 359,213 | Withhold |
| BlackRock | 0 | 0 | 343,025 | 0 | Abstain |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 0 | 0 | 329,949 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 128,300 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 55,214 | Withhold |
| T. Rowe Price | 0 | 0 | 0 | 33,600 | Withhold |
| Columbia Threadneedle | 18,007 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 16,475 | 0 | Abstain |
| MASTER INVESTMENT PORTFOLIO | 0 | 0 | 16,133 | 0 | Abstain |
| Equitable | 0 | 0 | 0 | 8,718 | Withhold |
| Northern Trust | 6,462 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 6,343 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 5,800 | Withhold |
| Nationwide | 0 | 0 | 0 | 5,228 | Withhold |
| Dimensional | 0 | 0 | 0 | 2,108 | Withhold |
| John Hancock | 0 | 0 | 919 | 0 | Abstain |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 208 | Withhold |
| Guggenheim | 0 | 0 | 0 | 156 | Withhold |
Combines 2 wordings of this item as funds reported it.
37% Not approved · of votes cast
Description as filed by funds: APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
PMV PHARMACEUTICALS INC.’s own tally for this item (“2. Non-Binding Advisory Vote to Approve the Compensation of the Company's Named Executive Officers On a non-binding advisory basis, the compensation paid to the Company's named executive officers as described in its defi”): 11,646,401 for, 20,170,398 against — failed, per its Form 8-K filed June 9, 2025 (Item 5.07).
Reported outcome: Not approved, in the filing’s own words: “Non-Binding Advisory Vote to Approve the Compensation of the Company's Named Executive Officers On a non-binding advisory basis, the compensation paid to the Company's named executive officers as described in its definitive proxy statement on Schedule 14A, filed with the U.S. Securities and Exchang…”
Support: 37% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 2,132,041 | 0 | 0 | Against |
| MERIDIAN FUND INC | 0 | 1,255,473 | 0 | 0 | Against |
| ACAP Strategic Fund | 0 | 1,147,095 | 0 | 0 | Against |
| Fidelity | 0 | 359,213 | 0 | 0 | Against |
| BlackRock | 265,445 | 77,580 | 0 | 0 | Mixed |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 329,949 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 0 | 128,300 | 0 | 0 | Against |
| Goldman Sachs | 0 | 55,214 | 0 | 0 | Against |
| T. Rowe Price | 0 | 33,600 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 18,007 | 0 | 0 | Against |
| Jackson National | 0 | 16,475 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 16,133 | 0 | 0 | 0 | For |
| Equitable | 0 | 8,718 | 0 | 0 | Against |
| Northern Trust | 0 | 6,462 | 0 | 0 | Against |
| Lincoln Financial | 0 | 6,343 | 0 | 0 | Against |
| Blackstone Alternative Investment Funds | 0 | 5,800 | 0 | 0 | Against |
| Nationwide | 0 | 5,228 | 0 | 0 | Against |
| Dimensional | 0 | 2,108 | 0 | 0 | Against |
| John Hancock | 0 | 919 | 0 | 0 | Against |
| Advisors' Inner Circle Fund III | 0 | 208 | 0 | 0 | Against |
| Guggenheim | 0 | 156 | 0 | 0 | Against |
Fund voting reports, all 21 managers: 281,578 for, 5,588,889 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 6,475,291 | 0 | 0 | 0 | For |
| PFM Health Sciences, LP | 0 | 3,301,942 | 0 | 0 | Against |
| ArrowMark Colorado Holdings LLC | 0 | 2,423,276 | 0 | 0 | Against |
| ALKEON CAPITAL MANAGEMENT LLC | 0 | 877,830 | 0 | 0 | Against |
| DE Shaw | 0 | 779,558 | 0 | 0 | Against |
| Stonepine Capital Management, LLC | 646,282 | 0 | 0 | 0 | For |
| Two Sigma | 0 | 644,081 | 0 | 0 | Against |
| Aldebaran Capital, LLC | 0 | 523,440 | 0 | 0 | Against |
| BlackRock | 272,441 | 238,409 | 0 | 0 | Mixed |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 403,915 | 0 | 0 | Against |
| PNC BANK, NATIONAL ASSOCIATION | 0 | 183,372 | 0 | 0 | Against |
| State Street | 151,786 | 5,792 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | 154,027 | 0 | 0 | Against |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 148,800 | 0 | 0 | Against |
| Maryland State Retirement & Pension System | 0 | 104,055 | 0 | 0 | Against |
| Dimensional | 0 | 89,909 | 0 | 0 | Against |
| PANAGORA ASSET MANAGEMENT INC | 0 | 89,631 | 0 | 0 | Against |
| Vanguard | 0 | 81,368 | 0 | 0 | Against |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0 | 64,383 | 0 | 0 | Against |
| Northern Trust | 0 | 45,220 | 0 | 0 | Against |
| Velan Capital Investment Management LP | 35,000 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 33,600 | 0 | 0 | Against |
| Goldman Sachs | 0 | 13,116 | 0 | 0 | Against |
| SEI | 0 | 7,738 | 0 | 0 | Against |
| Point72 | 0 | 7,236 | 0 | 0 | Against |
Institutional-manager reports, all 43 managers: 7,581,317 for, 10,234,863 against. Showing the 25 largest; every one is in the interactive database (link above).
98% Approved · of votes cast
Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT PUBLIC ACCOUNTING FIRM.
PMV PHARMACEUTICALS INC.’s own tally for this item (“3. Ratification of Independent Registered Public Accounting Firm”): 39,963,653 for, 638,940 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 21 asset managers below reported 5,870,467 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,132,041 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 1,255,473 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 1,147,095 | 0 | 0 | 0 | For |
| Fidelity | 359,213 | 0 | 0 | 0 | For |
| BlackRock | 343,025 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 329,949 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 128,300 | 0 | 0 | 0 | For |
| Goldman Sachs | 55,214 | 0 | 0 | 0 | For |
| T. Rowe Price | 33,600 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 18,007 | 0 | 0 | 0 | For |
| Jackson National | 16,475 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 16,133 | 0 | 0 | 0 | For |
| Equitable | 8,718 | 0 | 0 | 0 | For |
| Northern Trust | 6,462 | 0 | 0 | 0 | For |
| Lincoln Financial | 6,343 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 5,800 | 0 | 0 | 0 | For |
| Nationwide | 5,228 | 0 | 0 | 0 | For |
| Dimensional | 2,108 | 0 | 0 | 0 | For |
| John Hancock | 919 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 208 | 0 | 0 | 0 | For |
| Guggenheim | 156 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 51,952,680 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.10% |
| 2 | MERIDIAN FUND INC | 2.42% |
| 3 | ACAP Strategic Fund | 2.21% |
| 4 | Fidelity | 0.69% |
| 5 | BlackRock | 0.66% |
| 6 | Advantage Advisers Xanthus Fund, L.L.C. | 0.64% |
| 7 | BRIDGEWAY FUNDS INC | 0.25% |
| 8 | Goldman Sachs | 0.11% |
| 9 | T. Rowe Price | 0.06% |
| 10 | Columbia Threadneedle | 0.03% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 12.46% |
| 2 | PFM Health Sciences, LP | 6.36% |
| 3 | ArrowMark Colorado Holdings LLC | 4.66% |
| 4 | ALKEON CAPITAL MANAGEMENT LLC | 1.69% |
| 5 | DE Shaw | 1.50% |
| 6 | Stonepine Capital Management, LLC | 1.24% |
| 7 | Two Sigma | 1.24% |
| 8 | Aldebaran Capital, LLC | 1.01% |
| 9 | BlackRock | 0.98% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 0.78% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with OrbiMed Advisors | 12.46% | DEF14A |
| BML Investment Partners, L.P. | 10.19% | 13G |
| TANG CAPITAL MANAGEMENT, LLC | 9.09% | 13G |
| Entities affiliated with Sio Capital Management, LLC | 7.19% | DEF14A |
| ArrowMark Colorado Holdings, LLC | 5.95% | 13G |
| Sio Capital Management, LLC | 5.92% | 13G |
| Euclidean Capital LLC | 5.06% | 13G |
| Entities affiliated with PFM Health Sciences, LP | 5.00% | DEF14A |
| Vanguard Group | 4.19% | 13F |
| David H. Mack, Ph.D. | 4.01% | DEF14A |
Percentages above are of 51,952,680 shares outstanding, as reported by PMV PHARMACEUTICALS INC. on its Form 10-Q dated May 9, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PMV PHARMACEUTICALS INC.’s 10-Q dated May 9, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
PMV PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
proxyvotesnow.com, “PMV PHARMACEUTICALS (PMVP) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/pmv-pharmaceuticals-inc/2025 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.